自身免疫病相关性溃疡的临床特点及诊疗研究进展

赵令; 宿凯笙; 叶壮; 姜振宇; 陈露; 龙钰

doi:10.3760/cma.j.cn501120-20211019-00358

自身免疫病相关性溃疡的临床特点及诊疗研究进展

doi: 10.3760/cma.j.cn501120-20211019-00358

吉林大学第一医院风湿免疫科，长春　　130021

基金项目:

吉林省直卫生专项 JLSWSRCZX2020-0038

详细信息

通讯作者:
姜振宇，Email：jiangzhenyu2012@163.com

计量
- 文章访问数: 840
- HTML全文浏览量: 85
- PDF下载量: 56
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-19

Research advances on the clinical characteristics and diagnosis and treatment of autoimmune disease-related ulcers

Department of Rheumatology, the First Hospital of Jilin University, Changchun 130021, China

Funds:

Jilin Provincial Health Special Project JLSWSRCZX2020-0038

More Information

Corresponding author: Jiang Zhenyu, Email: jiangzhenyu2012@163.com

摘要

摘要: 研究显示，自身免疫病（AID）相关性溃疡是引发感染、残疾等严重不良预后的并发症。其明确诊断难度大，治疗上存在免疫抑制治疗与抗感染治疗的矛盾，不恰当的诊断、免疫抑制治疗易延误抗感染及手术治疗的时机，给患者预后带来不良影响。该文综述了AID相关性溃疡的概念、各亚型临床特点和处置建议等，以期为临床AID相关性溃疡的诊疗提供更多思路。
- 自身免疫疾病 /
- 皮肤溃疡 /
- 感染 /
- 伤口愈合
Abstract: Studies have shown that autoimmune disease (AID)-related ulcers are disease complications that lead to serious poor prognosis such as infection and disability. It is difficult to make a clear diagnosis and there are contradictions between the applications of immunosuppressive therapy and anti-infectious therapy. Improper diagnosis and immunosuppressive therapy can easily delay the timing of anti-infectious therapy and surgery for patients, which bring adverse effects on the prognosis of patients. This paper reviews the concept, clinical characteristics and treatment suggestions of each subtype of AID-related ulcers, in order to provide more ideas for AID-related ulcers' clinical diagnosis and treatment.
- Autoimmune diseases /
- Skin ulcer /
- Infection /
- Wound healing
所有作者均声明不存在利益冲突

·消息·

关于开展创面修复学科建设百千万五年行动计划的通知

为保障创面修复科等相关科室能力建设工作，进一步提升创面修复诊疗能力和规范化水平，加强慢性创面修复专业技术的推广，充分发挥继续教育在专科人才培养方面的重要作用，国家卫生健康委能力建设和继续教育中心组织相关专家共同开展调研分析，经多次研究论证，拟定于2022年5月—2027年4月开展创面修复学科建设百千万五年行动。该计划主要面向基层临床专科管理人员、医师、护士及相关技术人员开展创面修复相关技能培训，主要内容包括：（1）探索构建符合我国创面修复专科人才培养体系。（2）建立创面修复学科培训基地建设体系。（3）培养一批创面修复学科的优秀人才队伍和讲师团队。

项目联系人：郭常松，联系电话：010-83041862。具体情况详见《中华烧伤与创面修复杂志》网站：http://www.zhsszz.org/、http://zhsszz.xml-journal.net/及微信公众号。

国家卫生健康委能力建设和继续教育中心

HTML全文

参考文献(51)

[1]	SuzukiE,KyozukaH,NishidaT,et al.Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan[J].Mod Rheumatol,2009,19(4):447-451.DOI: 10.1007/s10165-009-0184-y.
[2]	LeaperDJ, SchultzG, CarvilleK, et al. Extending the TIME concept: what have we learned in the past 10 years?*[J]. Int Wound J, 2012,9 (Suppl 2):S1-19. DOI: 10.1111/j.1742-481X.2012.01097.x
[3]	BroughtonG2nd,JanisJE,AttingerCE.Wound healing: an overview[J].Plast Reconstr Surg,2006,117(7 Suppl):1e-S-32e-S.DOI: 10.1097/01.prs.0000222562.60260.f9.
[4]	MűzesG, SiposF. Primary immunodeficiency and autoimmune diseases[J]. Orv Hetil, 2018,159(23):908-918. DOI: 10.1556/650.2018.31064.
[5]	Amaya-UribeL,RojasM,AziziG,et al.Primary immunodeficiency and autoimmunity: a comprehensive review[J].J Autoimmun,2019,99:52-72.DOI: 10.1016/j.jaut.2019.01.011.
[6]	MaysJW,SarmadiM,MoutsopoulosNM.Oral manifestations of systemic autoimmune and inflammatory diseases: diagnosis and clinical management[J].J Evid Based Dent Pract,2012,12(3 Suppl):S265-282.DOI: 10.1016/S1532-3382(12)70051-9.
[7]	LoraV,CerroniL,CotaC.Skin manifestations of rheumatoid arthritis[J].G Ital Dermatol Venereol,2018,153(2):243-255.DOI: 10.23736/S0392-0488.18.05872-8.
[8]	GhoshSK, BandyopadhyayD, BiswasSK, et al. Mucocutaneous manifestations in patients with rheumatoid arthritis: a cross-sectional study from Eastern India[J]. Indian J Dermatol, 2017,62(4):411-417. DOI: 10.4103/ijd.IJD_260_17.
[9]	OlivéA,RiverosA,JuárezP,et al.Rheumatoid vasculitis: study of 41 cases[J].Med Clin (Barc),2020,155(3):126-129.DOI: 10.1016/j.medcli.2020.01.024.
[10]	Chua-AguileraCJ,MöllerB,YawalkarN.Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides[J].Clin Rev Allergy Immunol,2017,53(3):371-393.DOI: 10.1007/s12016-017-8632-5.
[11]	NarváezJ, Domingo-DomenechE, Gómez-VaqueroC, et al. Biological agents in the management of Felty's syndrome: a systematic review[J]. Semin Arthritis Rheum, 2012,41(5):658- 668. DOI: 10.1016/j.semarthrit.2011.08.008.
[12]	XueY,CohenJM,WrightNA,et al.Skin signs of rheumatoid arthritis and its therapy-induced cutaneous side effects[J].Am J Clin Dermatol,2016,17(2):147-162.DOI: 10.1007/s40257-015-0167-z.
[13]	SayahA,EnglishJC3rd.Rheumatoid arthritis: a review of the cutaneous manifestations[J].J Am Acad Dermatol,2005,53(2):191-209; quiz 210-212.DOI: 10.1016/j.jaad.2004.07.023.
[14]	SzekaneczZ,McInnesIB,SchettG,et al.Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases[J].Nat Rev Rheumatol,2021,17(10):585-595.DOI: 10.1038/s41584-021-00652-9.
[15]	GilliamJN,SontheimerRD.Distinctive cutaneous subsets in the spectrum of lupus erythematosus[J].J Am Acad Dermatol,1981,4(4):471-475.DOI: 10.1016/s0190-9622(81)80261-7.
[16]	SontheimerRD.The lexicon of cutaneous lupus erythematosus--a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus[J].Lupus,1997,6(2):84-95.DOI: 10.1177/096120339700600203.
[17]	NevskayaT,GambleMP,PopeJE.A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors[J].Clin Exp Rheumatol,2017,35(4):700-710.
[18]	KallasR,GoldmanD,PetriMA.Cutaneous vasculitis in SLE[J].Lupus Sci Med,2020,7(1):e000411.DOI: 10.1136/lupus-2020-000411.
[19]	CaproniM,VerdelliA.An update on the nomenclature for cutaneous vasculitis[J].Curr Opin Rheumatol,2019,31(1):46-52.DOI: 10.1097/BOR.0000000000000563.
[20]	JennetteJC,FalkRJ,BaconPA,et al.2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides[J].Arthritis Rheum,2013,65(1):1-11.DOI: 10.1002/art.37715.
[21]	ShiraiT,ShirotaY,FujiiH,et al.Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries[J].Scand J Rheumatol,2019,48(4):308-314.DOI: 10.1080/03009742.2018.1551965.
[22]	CriadoPR,MarquesGF,TCABMorita,et al.Epidemiological, clinical and laboratory profiles of cutaneous polyarteritis nodosa patients: report of 22 cases and literature review[J].Autoimmun Rev,2016,15(6):558-563.DOI: 10.1016/j.autrev.2016.02.010.
[23]	BulurI,OnderM.Behçet disease: new aspects[J].Clin Dermatol,2017,35(5):421-434.DOI: 10.1016/j.clindermatol.2017.06.004.
[24]	MatMC,SevimA,FreskoI,et al.Behçet's disease as a systemic disease[J].Clin Dermatol,2014,32(3):435-442.DOI: 10.1016/j.clindermatol.2013.11.012.
[25]	ObataS,KobayashiK,TodaM,et al.Genital ulcer of behçet disease localized in the vagina may lack pain, making it difficult to assess[J].Case Rep Rheumatol,2019,2019:2953676.DOI: 10.1155/2019/2953676.
[26]	BuntrockA,McNamaraM,TantoushH,et al.Worsening of behcet syndrome symptoms during pregnancy[J].S D Med,2021,74(3):112-114.
[27]	GeneraliE,CostanzoA,MainettiC,et al.Cutaneous and mucosal manifestations of Sjögren's syndrome[J].Clin Rev Allergy Immunol,2017,53(3):357-370.DOI: 10.1007/s12016-017-8639-y.
[28]	DamoiseauxJ.The diagnosis and classification of the cryoglobulinemic syndrome[J].Autoimmun Rev,2014,13(4/5):359-362.DOI: 10.1016/j.autrev.2014.01.027.
[29]	Ramos-CasalsM,Brito-ZerónP,SerorR,et al.Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements[J].Rheumatology (Oxford),2015,54(12):2230-2238.DOI: 10.1093/rheumatology/kev200.
[30]	CentalaS,ParkJH,GirnitaD.Sjogren's syndrome presenting with solely cutaneous features[J].Diagnostics (Basel),2021,11(7):1260.DOI: 10.3390/diagnostics11071260.
[31]	DeWaneME,WaldmanR,LuJ.Dermatomyositis: clinical features and pathogenesis[J].J Am Acad Dermatol,2020,82(2):267-281.DOI: 10.1016/j.jaad.2019.06.1309.
[32]	BogdanovI,KazandjievaJ,DarlenskiR,et al.Dermatomyositis: current concepts[J].Clin Dermatol,2018,36(4):450-458.DOI: 10.1016/j.clindermatol.2018.04.003.
[33]	KurtzmanDJB, VleugelsRA. Anti-melanoma differentiation- associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features[J].J Am Acad Dermatol,2018,78(4):776-785.DOI: 10.1016/j.jaad.2017.12.010.
[34]	NarangNS,Casciola-RosenL,LiSF,et al.Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation- associated gene 5 antibodies and interstitial lung disease[J].Arthritis Care Res (Hoboken),2015,67(5):667-672.DOI: 10.1002/acr.22498.
[35]	GuillevinL,HunscheE,DentonCP,et al.Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry[J].Clin Exp Rheumatol,2013,31(2 Suppl 76):S71-80.
[36]	MerkelPA,HerlynK,MartinRW,et al.Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon[J].Arthritis Rheum,2002,46(9):2410- 2420.DOI: 10.1002/art.10486.
[37]	PearsonDR,WerthVP,Pappas-TafferL.Systemic sclerosis: current concepts of skin and systemic manifestations[J].Clin Dermatol,2018,36(4):459-474.DOI: 10.1016/j.clindermatol.2018.04.004.
[38]	吴超,晋红中.坏疽性脓皮病的辅助检查及治疗[J].中华临床免疫和变态反应杂志,2019,13(4):301-305.DOI: 10.3969/j.issn.1673-8705.2019.04.010.
[39]	Julve-HerraizL,Villalba-FerrerF,García-CoretMJ,et al.Care and treatment of peristomal gangrenous pyoderma. A study of three cases[J].Enferm Clin (Engl Ed),2021,31(2):120-125.DOI: 10.1016/j.enfcli.2020.11.004.
[40]	唐锦明,祁少海,毛任翔,等.自身免疫性风湿病患者皮肤溃疡的临床特点与治疗策略[J/CD].中华损伤与修复杂志:电子版,2009,4(5):545-554.DOI: 10.3969/j.issn.1673-9450.2009.05.008.
[41]	VeselyMD.Getting under the skin: targeting cutaneous autoimmune disease[J].Yale J Biol Med,2020,93(1):197-206.
[42]	BusadaJT,CidlowskiJA.Mechanisms of glucocorticoid action during development[J].Curr Top Dev Biol,2017,125:147-170.DOI: 10.1016/bs.ctdb.2016.12.004.
[43]	Kowal-BieleckaO,FransenJ,AvouacJ,et al.Update of EULAR recommendations for the treatment of systemic sclerosis[J].Ann Rheum Dis,2017,76(8):1327-1339.DOI: 10.1136/annrheumdis-2016-209909.
[44]	StuckAE,MinderCE,FreyFJ.Risk of infectious complications in patients taking glucocorticosteroids[J].Rev Infect Dis,1989,11(6):954-963.DOI: 10.1093/clinids/11.6.954.
[45]	DerekE,DhanireddyK.Immunosuppression[J].Curr Opin Organ Transplant,2012,17(6):616-618.DOI: 10.1097/MOT.0b013e32835a7d3a.
[46]	SchuppeH,Richter-HintzD,StierleHE,et al.Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis[J].Rheumatology (Oxford),2000,39(1):105-106.DOI: 10.1093/rheumatology/39.1.105.
[47]	BettuzziT,JachietM,SbidianE,et al.Efficacy and safety of treatments in cutaneous polyarteritis nodosa: a French observational retrospective study[J].J Am Acad Dermatol,2022,86(5):1035-1041.DOI: 10.1016/j.jaad.2021.06.872.
[48]	GoldustM,HagstromEL,RathodD,et al.Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum[J].Expert Rev Clin Pharmacol,2020,13(2):157-161.DOI: 10.1080/17512433.2020.1709825.
[49]	OienRF,HåkanssonA,HansenBU.Leg ulcers in patients with rheumatoid arthritis--a prospective study of aetiology, wound healing and pain reduction after pinch grafting[J].Rheumatology (Oxford),2001,40(7):816-820.DOI: 10.1093/rheumatology/40.7.816.
[50]	HorwitzDA,FahmyTM,PiccirilloCA,et al.Rebalancing immune homeostasis to treat autoimmune diseases[J].Trends Immunol,2019,40(10):888-908.DOI: 10.1016/j.it.2019.08.003.
[51]	唐玉磊.褥疮护理新进展[J].中国老年保健医学,2007,5(4):143-144.DOI: 10.3969/j.issn.1672-4860-B.2007.04.091.